Opinion|Videos|December 21, 2024

Clinical Value of Biosimilars and the Role of Interchangeability

A panelist discusses how biosimilar adoption faces multiple barriers despite proven cost benefits, exploring strategies for improving uptake, best practices for interchangeability, experiences with adalimumab switching, and future optimization opportunities in healthcare systems.

Video content above is prompted by the following:

  • Biosimilars have been shown to reduce costs for patients and the healthcare system in general. Given that, why do you think the uptake of biosimilars is still relatively low?
  • How can the uptake of biosimilars into health systems be improved?
  • Interchangeability can be employed by pharmacists to switch a reference product with a biosimilar. What are your best practices for employing this in your practice?
  • What has your experience been like switching from adalimumab reference product to biosimilars?
  • How can switching from adalimumab reference product to biosimilars be improved in the future?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo